BRIEF-FDA Approves Pembrolizumab With Chemotherapy For Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma-March 2024-www.financetom.com

BRIEF-FDA Approves Pembrolizumab With Chemotherapy For Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-FDA Approves Pembrolizumab With Chemotherapy For Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma

Sep 20, 2024 10:33 PM

Sept 17 (Reuters) - U.S. Food and Drug Administration

(FDA):

* FDA APPROVES PEMBROLIZUMAB WITH CHEMOTHERAPY FOR

UNRESECTABLE

ADVANCED OR METASTATIC MALIGNANT PLEURAL MESOTHELIOMA

Further company coverage:

([email protected])

Previous page： TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences Next page： What's Going On With AMD Stock Wednesday?

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences

Oct 8, 2025

10:54 AM EDT, 10/08/2025 (MT Newswires) -- TransCode Therapeutics ( RNAZ ) said Wednesday it has agreed to buy biotechnology immuno-oncology company Polynoma from a subsidiary of CK Life Sciences. The company also announced a $25 million equity investment from CK Life Sciences for the clinical development of TransCode's lead microRNA asset, TTX-MC138, into a phase 2 clinical study. Under...

What's Going On With AMD Stock Wednesday?

Oct 8, 2025

Advanced Micro Devices Inc ( AMD ) shares are trading higher Wednesday morning, maintaining momentum from a significant surge earlier in the week following the announcement of a multi-year partnership with OpenAI. Here’s what investors need to know. What To Know: The deal, which could unlock over $100 billion in revenue for AMD, will see the chipmaker supply up to...

Eli Lilly's Q3 Results Expected to Meet Estimates as Mounjaro Outperforms, Deutsche Bank Says

Oct 8, 2025

10:59 AM EDT, 10/08/2025 (MT Newswires) -- Eli Lilly ( LLY ) is projected to report Q3 results broadly in line with Wall Street expectations, driven by a strong performance from diabetes drug Mounjaro and steady demand for obesity treatment Zepbound, Deutsche Bank said in a report Wednesday. Mounjaro is forecast to post a solid 3Q25 beat with resilient pricing,...

Market Chatter: Apollo Mulls Energy, Data Center Investment Opportunities in Spain

Oct 8, 2025

10:54 AM EDT, 10/08/2025 (MT Newswires) -- Apollo Global Management ( APO ) is eyeing potential investment opportunities in Spain related to energy transition, data centers and infrastructure, Bloomberg said Wednesday, citing the company's senior advisor for Iberia, Konstantin Sajonia-Coburgo. Speaking at Bloomberg's Future of Finance conference in Madrid, Sajonia-Coburgo said that with Spain's stock market representing 10% of the...